ResProt JMIR Res Protoc JMIR Research Protocols 1929-0748 JMIR Publications Toronto, Canada v10i12e33746 34898460 10.2196/33746 Protocol Protocol Multiplex Droplet Digital Polymerase Chain Reaction Assay for Rapid Molecular Detection of Pathogens in Patients With Sepsis: Protocol for an Assay Development Study Derrick Thomas Badran Samir BSc, MSc 1
Research Unit in Clinical Microbiology Department of Clinical Diagnostics Hospital South West Jutland, University Hospital of Southern Denmark Finensensgade 35 Esbjerg, 6700 Denmark 45 20996334 Samir.Badran2@rsyd.dk
2 https://orcid.org/0000-0002-5314-6789 Chen Ming MD, PhD 2 3 https://orcid.org/0000-0002-5393-1103 Coia John E BSc, MBChB, MD 1 2 https://orcid.org/0000-0002-4966-8453 Research Unit in Clinical Microbiology Department of Clinical Diagnostics Hospital South West Jutland, University Hospital of Southern Denmark Esbjerg Denmark Department of Regional Health Research Faculty of Health Sciences University of Southern Denmark Odense Denmark Department of Clinical Microbiology Hospital of Southern Jutland, University Hospital of Southern Denmark Aabenraa Denmark Corresponding Author: Samir Badran Samir.Badran2@rsyd.dk 12 2021 13 12 2021 10 12 e33746 22 9 2021 24 10 2021 ©Samir Badran, Ming Chen, John E Coia. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 13.12.2021. 2021

This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Research Protocols, is properly cited. The complete bibliographic information, a link to the original publication on https://www.researchprotocols.org, as well as this copyright and license information must be included.

 Background

Blood cultures are the cornerstone of diagnosis for detecting the presence of bacteria or fungi in the blood, with an average detection time of 48 hours and failure to detect a pathogen occurring in approximately 50% of patients with sepsis. Rapid diagnosis would facilitate earlier treatment and/or an earlier switch to narrow-spectrum antibiotics.

 Objective

The aim of this study is to develop and implement a multiplex droplet digital polymerase chain reaction (ddPCR) assay as a routine diagnostic tool in the detection and identification of pathogens from whole blood and/or blood culture after 3 hours of incubation.

 Methods

The study consists of three phases: (1) design of primer-probe pairs for accurate and reliable quantification of the most common sepsis-causing microorganisms using a multiplex reaction, (2) determination of the analytical sensitivity and specificity of the multiplex ddPCR assay, and (3) a clinical study in patients with sepsis using the assay. The QX200 Droplet Digital PCR System will be used for the detection of the following species-specific genes in blood from patients with sepsis: coa (staphylocoagulase) in Staphylococcus aureus, cpsA (capsular polysaccharide) in Streptococcus pneumoniae, uidA (beta-D-glucuronidase) in Escherichia coli, oprL (peptidoglycan-associated lipoprotein) in Pseudomonas aeruginosa, and the highly conserved regions of the 16S rRNA gene for Gram-positive and Gram-negative bacteria. All data will be analyzed using QuantaSoft Analysis Pro Software.

 Results

In phase 1, to determine the optimal annealing temperature for the designed primer-probe pairs, results from a gradient temperature experiment will be collected and the limit of detection (LOD) of the assay will be determined. In phase 2, results for the analytical sensitivity and specificity of the assay will be obtained after an optimization of the extraction and purification method in spiked blood. In phase 3, clinical sensitivity and specificity as compared to the standard blood culture technique will be determined using 301 clinical samples.

 Conclusions

Successful design of primer-probe pairs in the first phase and subsequent optimization and determination of the LOD will allow progression to phase 3 to compare the novel method with existing blood culture methods.

 International Registered Report Identifier (IRRID)

PRR1-10.2196/33746

 sepsis ddPCR clinical microbiology molecular diagnostics infectious diseases ext-peer-rev This paper was peer reviewed by the University of Southern Denmark, Graduate School - Faculty of Health Sciences. See the Multimedia Appendix for the peer-review report; Introduction

Sepsis, a dysregulated host response to infection leading to life-threatening organ dysfunction [1], often caused by bloodstream infection (BSI), is a major public health concern worldwide. Sepsis affects more than 48 million people annually, including an estimated 3 million newborns, leading to more than 11 million deaths annually, mainly in a hospital setting [2,3]. This makes it one of the leading causes of death worldwide [4]. In Denmark, the incidence rate is estimated to be 56,145 cases per year with a mortality of 8085, potentially accounting for 15% of all deaths [5,6].

Most sepsis survivors experience additional morbidities, resulting in reduced physical and mental quality of life after diagnosis [7,8]. Up to 32% of patients with sepsis have a rehospitalization episode within 30 days and 60% are readmitted at least once within one year [8]. According to a Danish study by Perner et al [9], more than 50% of sepsis survivors die in the first year following diagnosis. The significant burden of morbidity and mortality from sepsis has a profound impact on patients and their families, and it is a substantial economic burden on health care systems and society [10].

Sepsis is a profound inflammatory response to infections caused by bacterial, viral, fungal, or parasitic pathogens [11]. One of the primary reasons for the high morbidity and mortality rate of sepsis is delay in diagnosis and initiation of antimicrobial therapy—every hour of delay in appropriate antimicrobial treatment increases mortality by 7.6% [12,13]. As many as 80% of sepsis deaths could be prevented with rapid diagnosis and treatment [14]. During BSI, the bacterial load is estimated to be 1-10 CFU/mL [15] or 103 to 104 copies of bacterial DNA/mL [16]. Blood cultures are the cornerstone of microbiological diagnosis of sepsis. Key limitations are low sensitivity and long detection time (24-72 hours), with failure to detect a pathogen occurring in approximately 50% of patients with sepsis [15,17,18]. Gupta et al [19] have shown that sepsis-associated mortality was significantly higher in patients with a negative blood culture (34.6%) compared to patients with a positive blood culture (22.7%). Infection with fastidious microorganisms, antimicrobial treatment prior to blood collection, and low bacterial load all contribute to the occurrence of false-negative blood culture [15,20].

Multiplex real-time quantitative polymerase chain reaction (qPCR) has been increasingly employed in combination with positive blood culture to increase diagnostic sensitivity in patients with sepsis [21]. Multiplex qPCR also facilitates more rapid diagnosis [21-23], as demonstrated for the commercially available Septifast (Roche Diagnostics) [24] and FilmArray Blood Culture ID Panel (BCID; BioFire Diagnostics) [25]. The use of multiplex qPCR demonstrated high concordance with the blood culture technique, with up to 100% specificity and a limit of detection (LOD) ranging from 1 to 10 CFU/reaction [22,24]. It has been reported in some studies that multiplex qPCR detected the presence of a pathogen in 10%-40% of cases that were negative by conventional blood culture [26-28]. However, other studies have shown a reduced sensitivity, ranging from 28%-66%, in comparison with conventional blood cultures [28-30]. It is apparent that there is still a need for techniques to improve the diagnostic yield and reduce the time to diagnosis from blood culture specimens. The combination of nanoliter-sized droplet technology paired with digital polymerase chain reaction (PCR), known as droplet digital PCR (ddPCR), is a novel diagnostic tool that partitions the reaction into up to 20,000 droplets before amplification [31]. This method provides absolute quantification of target sequences and has demonstrated greater sensitivity, reproducibility, precision, and accuracy compared to qPCR [32-34]. For instance, the sensitivity of ddPCR was 6.4 copies/20 μL reaction for plasmid DNA and 5 CFUs/20 μL reaction for bacterial cells as compared to 12 copies/20 μL reaction and 36 CFUs/20 μL reaction using qPCR, respectively [35]. Furthermore, a study by Dong-Ku et al [36] demonstrated that, by using droplet digital detection technology, they were able to detect bacteria at the single-cell level in unprocessed diluted blood.

Recently, ddPCR has been investigated as a novel technique for the detection of pathogens in BSI. Wouters et al [37] demonstrated an overall sensitivity and specificity of 80% and 87%, respectively. Furthermore, they were able to detect Escherichia coli at a 10- to 100-fold lower concentration when compared to qPCR and with a detection limit of approximately 1-2 bacteria. Zhang et al [38] demonstrated similar results, with a detection rate up to 80%-90% of Staphylococcus aureus and E coli in blood when using ddPCR; both studies had promising results.

In this study, we will investigate ddPCR as a novel technique for sepsis diagnosis from whole blood and blood culture after 3 and 72 hours of incubation. To the best of our knowledge, this would be the first study that involves developing and implementing a multiplex ddPCR assay as a routine diagnostic tool for early detection of the most common sepsis-causing pathogens (ie, S aureus, Streptococcus pneumoniae, E coli, and Pseudomonas aeruginosa) in patients with sepsis. We believe that the technique will subsequently support clinicians to initiate early and rational antimicrobial treatment by reducing processing time and increasing the detection rate in blood cultures. Improved microbiological diagnosis of sepsis will not only help improve outcomes for sepsis, but also will contribute to improved antimicrobial stewardship and rational antibiotic prescribing.

 Methods

This study will be conducted in three phases (for flowchart, see Figure 1).

Flowchart showing the three phases of the study, consisting of the development of the assay in phase 1, validation of the assay in phase 2, and a clinical trial using the assay in phase 3. ddPCR: droplet digital polymerase chain reaction.

 Phase 1: Establishment of the Multiplex ddPCR Assay for the Detection of Quantitative Bacterial Genomic DNA and Determination of the LOD

In this phase, we will develop a novel multiplex ddPCR assay for accurate and reliable quantification of the genomic DNA of the most common sepsis-causing pathogens in our hospital region (ie, S aureus, S pneumoniae, E coli, and P aeruginosa) from cultured blood. This phase will be conducted in collaboration with the Department of Biochemistry, Hospital of Lillebaelt, Vejle, Denmark, since our laboratory facility does not currently have the QX200 Droplet Digital PCR System (Bio-Rad). This phase will include the following steps:

Design of primers and probes for the amplification of species-specific genes—that is, coa (staphylocoagulase) in S aureus, cpsA (capsular polysaccharide) in S pneumoniae, uidA (beta-D-glucuronidase) in E coli, oprL (peptidoglycan-associated lipoprotein) in P aeruginosa, and the highly conserved regions of the 16S rRNA gene for Gram-positive and Gram-negative bacteria.

Determination of the optimal thermocycling conditions for all primer pairs by varying the annealing temperature, extension time, and number of cycles.

Determination of the LOD of the assay by using a series of 10-fold serial dilutions of quantitative genomic DNA from a well-characterized stock (105 copies/µL). The serial dilutions of the stock will also be aliquoted and used as positive controls in subsequent analyses.

Determination of the rate at which false positives occur per run by analyzing a whole 96-well plate containing only nontemplate controls (ie, saline and uninfected cultured blood samples). Based on the evidence from this experiment, criteria for samples considered to be positive will be determined.

In this phase, primer-probe pairs for the targets of coa, cpsA, uidA, and oprL were designed using AlleleID (version 7.85; PREMIER Biosoft). The following ATCC strains were used for preliminary validation and testing of the designed primer-probe pairs: ATCC 29213 (S aureus), 49619 (S pneumoniae), 25922 (E coli), and 27853 (P aeruginosa).

 Phase 2: Determination of the Analytical Sensitivity and Specificity of the Multiplex ddPCR Assay Compared to the Blood Culture Technique and BCID Assay in Spiked Blood

This phase will be divided into two parts.

Part A

In order to determine the analytical sensitivity and specificity of the multiplex ddPCR assay in cultured clinical samples, we will establish and optimize a procedure for the extraction and purification of bacterial genomic DNA from blood cultures in spiked blood. To confirm the adequacy of the purification procedure, the spiked blood will be compared to saline samples of the chosen bacteria of 1, 5, 10, and 102 CFU/mL from 5 healthy/noninfected donors. Certified reference materials for the spiking of blood samples will be used.

 Part B

To validate the multiplex ddPCR assay, the analytical sensitivity and specificity will be compared to the blood culture technique and the BCID assay. For this study, a total of 50 blood samples (two BD BACTEC bottles corresponding to 20 mL and 1 mL of whole blood) from healthy/noninfected donors will be used. A total of 48 samples will be spiked with S aureus, S pneumoniae, E coli, and P aeruginosa (12 samples per bacteria) in triplicates of each concentration (ie, 1, 5, 10, and 102 CFU/mL). Two samples will be cultured with saline as nontemplate controls. All samples will be analyzed in duplicate by the multiplex ddPCR and BCID assay in parallel with blood cultures.

 Phase 3: Multiplex ddPCR for Rapid Identification of Pathogens in Cultured Blood and Comparison of the Rate of Detection of Pathogens by Multiplex ddPCR With Conventional Blood Culture in Patients With Sepsis Overview

This phase will investigate the use of the developed multiplex ddPCR assay for clinical samples from 301 patients with suspected sepsis. Patients will be selected for inclusion based on the following criteria: aged ≥18 years, lactate ≥2 mmol/L, and meet at least two of the following criteria, based on scores on the quick Sepsis-related Organ Failure Assessment (qSOFA): hypotension (systolic blood pressure ≤100 mm Hg), respiratory rate ≥22 breaths/minute, or altered mental status [1]. Patients will be excluded if they have no clinical or laboratory signs of sepsis.

The experiment will be blinded, and the results of the ddPCR assay will not be available to the clinical teams before the end of the study. This phase will be divided into two parts (for flowchart, see Figure 2).

Flowchart showing the study design of the clinical trial in phase 3, including patient selection, molecular detection divided into two parts (whole blood and incubation of blood cultures), and data analysis. ddPCR: droplet digital polymerase chain reaction; qSOFA: quick Sepsis-related Organ Failure Assessment.

 Part A

The multiplex ddPCR assay will be performed directly on 1 mL of whole blood, and again after 3 hours of incubation in BD BACTEC blood culture bottles. The results of these tests will be compared with those obtained after 72 hours of incubation in conventional blood cultures to compare the rate of detection in clinical samples.

 Part B

For Part B, 1 mL from conventional blood cultures that remained negative after day 3 will be analyzed retrospectively by ddPCR to confirm negative results [39]. Based on previous studies [26-28] showing that 10%-40% of negative blood cultures were found to be positive using a multiplex qPCR assay, we anticipate that at least 10% of those bottles that are negative by conventional culture will be positive using the multiplex ddPCR assay [32-35]. Data on antibiotic treatment and routine laboratory analyses will be extracted from clinical records and evaluated after collection and analysis of all blood samples. Data from the ddPCR assay will be analyzed using QuantaSoft Analysis Pro Software (Bio-Rad).

The sample size was calculated using Statulator, an online tool, with a power of 80% and a significance level of 5%. The calculation is based on the assumption that 15% and 20% of the pairs are positive by blood culture and ddPCR, respectively, and that the correlation between paired observations is 70%.

 Patient and Public Involvement

Patients and the public were not involved in the design or conduct of the study in any way, since the clinical trial will not influence patient management decisions. Therefore, the results will not be disseminated to the study participants.

 Timeline

The outlined study will be conducted as a regional study within the Region of Southern Denmark. For this study, six months will be allocated to phase 1, five months to phase 2, and 16 months to phase 3. Finally, 14 months in total will be allocated for writing articles in parallel with the experiments. The study started in February 2021.

 Ethics and Dissemination

Blood samples from healthy/noninfected donors will be anonymized and only used for spiking and nontemplate controls. All samples in phase 3 will be collected as part of routine diagnosis and management of patients, and the ddPCR results will not influence patient management decisions. Blood samples from patients with suspected sepsis will be pseudonymized and only used for method comparison. The Regional Committees on Health Research Ethics for Southern Denmark have notified for permission to conduct the study. Since the clinical study in phase 3 will not influence patient management decisions, no approval is required according to the Regional Committees on Health Research Ethics for Southern Denmark.

The results and findings from phases 1, 2, and 3 are expected to be published in peer-reviewed journals, preferably open access. National and at least two international conferences will be attended to present results and liaise with the scientific community. Science channels and the news will also be used to disseminate results.

 Results Phase 1: Establishment of the Multiplex ddPCR Assay for the Detection of Quantitative Bacterial Genomic DNA and Determination of the LOD

In phase 1, results from a gradient temperature experiment will be collected to determine the optimal annealing temperature for the designed primer-probe pairs. In addition, the results for the LOD of the multiplex assay will be obtained.

 Phase 2: Determination of the Analytical Sensitivity and Specificity of the Multiplex ddPCR Assay Compared to the Blood Culture Technique and BCID Assay in Spiked Blood

In phase 2, results of the optimized extraction and purification method will be presented and the analytical sensitivity and specificity of the multiplex assay will be obtained using spiked blood samples.

 Phase 3: Multiplex ddPCR for Rapid Identification of Pathogens in Cultured Blood and Comparison of the Rate of Detection of Pathogens by Multiplex ddPCR With Conventional Blood Culture in Patients With Sepsis

In phase 3, the clinical sensitivity and specificity of the multiplex ddPCR assay will be obtained and compared with the blood culture technique using 301 clinical samples.

This study is expected to conclude in February 2024.

 Discussion

Successful design of primer-probe pairs for a multiplex reaction in the first phase—and subsequent optimization and determination of the LOD—will allow progression to phase 2 to determine the analytical sensitivity and specificity of the assay, which will allow progression to phase three to compare the method with existing blood culture methods.

Peer-reviewer report from the University of Southern Denmark, Graduate School - Faculty of Health Sciences.

 Abbreviations BCID

Blood Culture ID Panel

 BSI

bloodstream infection

 ddPCR

droplet digital polymerase chain reaction

 LOD

limit of detection

 PCR

polymerase chain reaction

 qPCR

quantitative polymerase chain reaction

 qSOFA

quick Sepsis-related Organ Failure Assessment

This work is supported and funded by Region of Southern Denmark (grant number 20/14813), Hospital South West Jutland (grant BF/LH), A.P. Moller Fund (grant 20-L-0274), and Knud & Edith Mindefond (grant 62786-2020).

SB wrote the protocol. All authors contributed equally to the conception and design of the protocol. The protocol was revised critically for important intellectual content by MC and JEC.

None declared.

 Singer M Deutschman CS Seymour CW Shankar-Hari M Annane D Bauer M Bellomo R Bernard GR Chiche J Coopersmith CM Hotchkiss RS Levy MM Marshall JC Martin GS Opal SM Rubenfeld GD van der Poll T Vincent J Angus DC The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) JAMA 2016 02 23 315 8 801 10 10.1001/jama.2016.0287 26903338 2492881 PMC4968574 Rudd KE Johnson SC Agesa KM Shackelford KA Tsoi D Kievlan DR Colombara DV Ikuta KS Kissoon N Finfer S Fleischmann-Struzek C Machado FR Reinhart KK Rowan K Seymour CW Watson RS West TE Marinho F Hay SI Lozano R Lopez AD Angus DC Murray CJL Naghavi M Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study Lancet 2020 01 18 395 10219 200 211 10.1016/S0140-6736(19)32989-7 31954465 S0140-6736(19)32989-7 PMC6970225 Fleischmann-Struzek C Goldfarb DM Schlattmann P Schlapbach LJ Reinhart K Kissoon N The global burden of paediatric and neonatal sepsis: a systematic review Lancet Respir Med 2018 03 6 3 223 230 10.1016/S2213-2600(18)30063-8 29508706 S2213-2600(18)30063-8 GBD 2013 Mortality and Causes of Death Collaborators Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013 Lancet 2015 01 10 385 9963 117 71 10.1016/S0140-6736(14)61682-2 25530442 S0140-6736(14)61682-2 PMC4340604 Henriksen DP Laursen CB Jensen TG Hallas J Pedersen C Lassen AT Incidence rate of community-acquired sepsis among hospitalized acute medical patients-a population-based survey Crit Care Med 2015 01 43 1 13 21 10.1097/CCM.0000000000000611 25251760 Perner A Lassen A Schierbeck J Storgaard M Reiter N Benfield T Sygdomsbyrde og definitioner af sepsis hos voksne Ugeskr Laeger Apr 2018 04 2019-03-10 https://ugeskriftet.dk/files/scientific_article_files/2018-05/V09170685.pdf Wittbrodt P Haase N Butowska D Winding R Poulsen JB Perner A 6S trial group Scandinavian Critical Care Trials Group Quality of life and pruritus in patients with severe sepsis resuscitated with hydroxyethyl starch long-term follow-up of a randomised trial Crit Care 2013 02 25 17 2 R58 10.1186/cc12586 23531324 cc12586 PMC3672692 Shankar-Hari M Rubenfeld GD Understanding Long-Term Outcomes Following Sepsis: Implications and Challenges Curr Infect Dis Rep 2016 11 6 18 11 37 10.1007/s11908-016-0544-7 27709504 10.1007/s11908-016-0544-7 PMC5052282 Perner A Haase N Winkel P Guttormsen AB Tenhunen J Klemenzson G Müller RG Aneman A Wetterslev J Long-term outcomes in patients with severe sepsis randomised to resuscitation with hydroxyethyl starch 130/0.42 or Ringer's acetate Intensive Care Med 2014 07 8 40 7 927 34 10.1007/s00134-014-3311-y 24807084 Tiru B DiNino EK Orenstein A Mailloux PT Pesaturo A Gupta A McGee WT The Economic and Humanistic Burden of Severe Sepsis Pharmacoeconomics 2015 09 3 33 9 925 37 10.1007/s40273-015-0282-y 25935211 Chun K Syndergaard C Damas C Trubey R Mukindaraj A Qian S Jin X Breslow S Niemz A Sepsis Pathogen Identification J Lab Autom 2015 10 20 5 539 61 10.1177/2211068214567345 25631157 2211068214567345 Kumar A Roberts D Wood KE Light B Parrillo JE Sharma S Suppes R Feinstein D Zanotti S Taiberg L Gurka D Kumar A Cheang M Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock Crit Care Med 2006 06 34 6 1589 96 10.1097/01.CCM.0000217961.75225.E9 16625125 Weiss SL Fitzgerald JC Balamuth F Alpern ER Lavelle J Chilutti M Grundmeier R Nadkarni VM Thomas NJ Delayed antimicrobial therapy increases mortality and organ dysfunction duration in pediatric sepsis Crit Care Med 2014 11 42 11 2409 17 10.1097/CCM.0000000000000509 25148597 PMC4213742 Sepsis Fact Sheet Sepsis Alliance 2019-03-15 https://www.sepsis.org/education/resources/?resource_type=fact-sheet Opota O Jaton K Greub G Microbial diagnosis of bloodstream infection: towards molecular diagnosis directly from blood Clinical Microbiology and Infection 2015 04 21 4 323 331 10.1016/j.cmi.2015.02.005 Bacconi A Richmond GS Baroldi MA Laffler TG Blyn LB Carolan HE Frinder MR Toleno DM Metzgar D Gutierrez JR Massire C Rounds M Kennel NJ Rothman RE Peterson S Carroll KC Wakefield T Ecker DJ Sampath R Improved sensitivity for molecular detection of bacterial and Candida infections in blood J Clin Microbiol 2014 09 52 9 3164 74 10.1128/JCM.00801-14 24951806 JCM.00801-14 PMC4313132 Opota O Croxatto A Prod'hom G Greub G Blood culture-based diagnosis of bacteraemia: state of the art Clin Microbiol Infect 2015 04 21 4 313 22 10.1016/j.cmi.2015.01.003 25753137 S1198-743X(15)00183-4 Jamal W Tamaray G Pazhoor A Rotimi V Comparative evaluation of BacT/ALERT 3D and BACTEC systems for the recovery of pathogens causing bloodstream infections Med Princ Pract 2006 4 28 15 3 223 7 10.1159/000092186 16651840 92186 Gupta S Sakhuja A Kumar G McGrath E Nanchal RS Kashani KB Culture-Negative Severe Sepsis: Nationwide Trends and Outcomes Chest 2016 12 150 6 1251 1259 10.1016/j.chest.2016.08.1460 27615024 S0012-3692(16)58956-9 Moter A Musci M Schmiedel D Molecular methods for diagnosis of infective endocarditis Curr Infect Dis Rep 2010 07 13 12 4 244 52 10.1007/s11908-010-0111-6 21308538 Tat Trung N Van Tong H Lien TT Van Son T Thanh Huyen TT Quyen DT Hoan PQ Meyer CG Song LH Clinical utility of an optimised multiplex real-time PCR assay for the identification of pathogens causing sepsis in Vietnamese patients Int J Infect Dis 2018 02 67 122 128 10.1016/j.ijid.2017.12.015 29253706 S1201-9712(17)30327-2 van den Brand M Peters RP Catsburg A Rubenjan A Broeke FJ van den Dungen FA van Weissenbruch MM van Furth AM Kõressaar T Remm M Savelkoul PH Bos MP Development of a multiplex real-time PCR assay for the rapid diagnosis of neonatal late onset sepsis J Microbiol Methods 2014 11 106 8 15 10.1016/j.mimet.2014.07.034 25102109 S0167-7012(14)00230-9 van de Groep K Bos MP Savelkoul PHM Rubenjan A Gazenbeek C Melchers WJG van der Poll T Juffermans NP Ong DSY Bonten MJM Cremer OL MARS consortium Development and first evaluation of a novel multiplex real-time PCR on whole blood samples for rapid pathogen identification in critically ill patients with sepsis Eur J Clin Microbiol Infect Dis 2018 07 26 37 7 1333 1344 10.1007/s10096-018-3255-1 29700761 10.1007/s10096-018-3255-1 PMC6015113 Korber F Zeller I Grünstäudl M Willinger B Apfalter P Hirschl AM Makristathis A SeptiFast versus blood culture in clinical routine - A report on 3 years experience Wien Klin Wochenschr 2017 06 27 129 11-12 427 434 10.1007/s00508-017-1181-3 28243751 10.1007/s00508-017-1181-3 PMC5486735 Altun O Almuhayawi M Ullberg M Ozenci V Clinical evaluation of the FilmArray blood culture identification panel in identification of bacteria and yeasts from positive blood culture bottles J Clin Microbiol 2013 12 51 12 4130 6 10.1128/JCM.01835-13 24088863 JCM.01835-13 PMC3838040 Bloos F Sachse S Kortgen A Pletz MW Lehmann M Straube E Riedemann NC Reinhart K Bauer M Evaluation of a polymerase chain reaction assay for pathogen detection in septic patients under routine condition: an observational study PLoS One 2012 9 27 7 9 e46003 10.1371/journal.pone.0046003 23029360 PONE-D-12-10971 PMC3459981 Wellinghausen N Kochem A Disqué C Mühl H Gebert S Winter J Matten J Sakka SG Diagnosis of bacteremia in whole-blood samples by use of a commercial universal 16S rRNA gene-based PCR and sequence analysis J Clin Microbiol 2009 09 47 9 2759 65 10.1128/JCM.00567-09 19571030 JCM.00567-09 PMC2738079 Nieman AE Savelkoul PHM Beishuizen A Henrich B Lamik B MacKenzie CR Kindgen-Milles D Helmers A Diaz C Sakka SG Schade RP A prospective multicenter evaluation of direct molecular detection of blood stream infection from a clinical perspective BMC Infect Dis 2016 06 30 16 1 314 10.1186/s12879-016-1646-4 27364885 10.1186/s12879-016-1646-4 PMC4928256 Leitner E Kessler HH Spindelboeck W Hoenigl M Putz-Bankuti C Stadlbauer-Köllner V Krause R Grisold AJ Feierl G Stauber RE Comparison of two molecular assays with conventional blood culture for diagnosis of sepsis J Microbiol Methods 2013 03 92 3 253 5 10.1016/j.mimet.2012.12.012 23266578 S0167-7012(12)00408-3 Morrissey SM Nielsen M Ryan L Al Dhanhani H Meehan M McDermott S O'Sullivan N Doyle M Gavin P O'Sullivan N Cunney R Drew RJ Group B streptococcal PCR testing in comparison to culture for diagnosis of late onset bacteraemia and meningitis in infants aged 7-90 days: a multi-centre diagnostic accuracy study Eur J Clin Microbiol Infect Dis 2017 07 1 36 7 1317 1324 10.1007/s10096-017-2938-3 28247153 10.1007/s10096-017-2938-3 Hindson BJ Ness KD Masquelier DA Belgrader P Heredia NJ Makarewicz AJ Bright IJ Lucero MY Hiddessen AL Legler TC Kitano TK Hodel MR Petersen JF Wyatt PW Steenblock ER Shah PH Bousse LJ Troup CB Mellen JC Wittmann DK Erndt NG Cauley TH Koehler RT So AP Dube S Rose KA Montesclaros L Wang S Stumbo DP Hodges SP Romine S Milanovich FP White HE Regan JF Karlin-Neumann GA Hindson CM Saxonov S Colston BW High-throughput droplet digital PCR system for absolute quantitation of DNA copy number Anal Chem 2011 11 15 83 22 8604 10 10.1021/ac202028g 22035192 PMC3216358 Mu D Yan L Tang H Liao Y A sensitive and accurate quantification method for the detection of hepatitis B virus covalently closed circular DNA by the application of a droplet digital polymerase chain reaction amplification system Biotechnol Lett 2015 10 18 37 10 2063 73 10.1007/s10529-015-1890-5 26187315 10.1007/s10529-015-1890-5 Arvia R Sollai M Pierucci F Urso C Massi D Zakrzewska K Droplet digital PCR (ddPCR) vs quantitative real-time PCR (qPCR) approach for detection and quantification of Merkel cell polyomavirus (MCPyV) DNA in formalin fixed paraffin embedded (FFPE) cutaneous biopsies J Virol Methods 2017 08 246 15 20 10.1016/j.jviromet.2017.04.003 28414163 S0166-0934(16)30596-1 Taylor SC Laperriere G Germain H Droplet Digital PCR versus qPCR for gene expression analysis with low abundant targets: from variable nonsense to publication quality data Sci Rep 2017 05 25 7 1 2409 10.1038/s41598-017-02217-x 28546538 10.1038/s41598-017-02217-x PMC5445070 Zhao Y Xia Q Yin Y Wang Z Comparison of Droplet Digital PCR and Quantitative PCR Assays for Quantitative Detection of Xanthomonas citri Subsp. citri PLoS One 2016 7 18 11 7 e0159004 10.1371/journal.pone.0159004 27427975 PONE-D-16-05242 PMC4948846 Kang D Ali MM Zhang K Huang SS Peterson E Digman MA Gratton E Zhao W Rapid detection of single bacteria in unprocessed blood using Integrated Comprehensive Droplet Digital Detection Nat Commun 2014 11 13 5 1 5427 10.1038/ncomms6427 25391809 ncomms6427 PMC4243214 Wouters Y Dalloyaux D Christenhusz A Roelofs HMJ Wertheim HF Bleeker-Rovers CP Te Morsche RH Wanten GJA Droplet digital polymerase chain reaction for rapid broad-spectrum detection of bloodstream infections Microb Biotechnol 2020 05 13 3 657 668 10.1111/1751-7915.13491 31605465 PMC7111091 Zhang T Niu Z Wu F Chen Z Xu J Jiang K Lai Z Qualitative and quantitative detection of surgical pathogenic microorganisms Escherichia coli and Staphylococcus aureus based on ddPCR system Sci Rep 2021 04 22 11 1 8771 10.1038/s41598-021-87824-5 33888753 10.1038/s41598-021-87824-5 PMC8062461 Kirn T Weinstein M Update on blood cultures: how to obtain, process, report, and interpret Clin Microbiol Infect 2013 06 19 6 513 20 10.1111/1469-0691.12180 23490046 S1198-743X(14)61509-3